Product Information
HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.1354 per EA under NDC 64380044101. Its NADAC has been published 52 times since Oct 8, 2025.
FDA first approved this application on Jun 15, 2016. Its Orange Book therapeutic-equivalence code is AA.
Strength
325; 7.5 mg/1; mg/1
Manufacturer
Strides Pharma Inc.NDC
64380044101
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; HYDROCODONE BITARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA202935FDA Approved
6/15/2016
TE Code
AA
On Market Since
9/1/2025
Pharmacological Classes
Price Statistics
The NADAC for HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET has been published 52 times since Oct 8, 2025, and over the history we have for it it has declined 11.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1354 per EA |
|---|---|
| All-time high | $0.1522 (Oct 15, 2025) |
| All-time low | $0.1354 (Sep 23, 2026) |
| 52-week high | $0.1522 |
| 52-week low | $0.1354 |
| Median price | $0.1389 |
| Average price | $0.1413 |
| Largest weekly change | -4.2% (Dec 17, 2025) |
| Weeks tracked | 52 |
| Tracking since | Oct 8, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the hydrocodone bitartrate and acetaminophen market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
hydrocodone bitartrate and acetaminophen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET, manufactured by Strides Pharma Inc., is $0.1354 per EA (NDC 64380044101), effective Sep 30, 2026.
How has the price of HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET changed over time?
Over the history we have for it, the NADAC for HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET has declined 11.0%. It has been tracked across 52 weekly CMS publications since Oct 8, 2025.
What are the highest and lowest recorded NADAC prices for HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET?
Since Oct 8, 2025, the NADAC for HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET has ranged from a low of $0.1354 (Sep 23, 2026) to a high of $0.1522 (Oct 15, 2025), with a median of $0.1389 per EA.
Are there cheaper alternatives to HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET?
HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET (NDC 64380044101) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.